Medpace Holdings Inc. (MEDP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Medpace Holdings Inc. (MEDP) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How MEDP Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | 44% | 21.1% | $451.1M | $681.9M | 65.6% |
| FY 2024 | $2.11B | 44% | 21.2% | $404.4M | $572.3M | 48.4% |
| FY 2023 | $1.89B | 44% | 17.9% | $282.8M | $348.5M | 4.2% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MEDP)
- ✓Live walkthrough of MEDP's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
MEDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MEDP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MEDP. Explore sector supply chains on /butterfly.
MEDP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Medpace Holdings Inc. (MEDP)?
In FY 2025 (10-K), MEDP converted $2.5B of revenue into a 44% gross margin, 21.1% operating margin, and $681.9M in free cash flow (26.9% FCF margin).